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Abstract
Background: A number of diagnostic tests are required for the detection and management of cancer. Most
imaging modalities such as computerized tomography (CT) are anatomical. However, positron emission
tomography (PET) is a functional diagnostic imaging technique using compounds labelled with positron-emitting
radioisotopes to measure cell metabolism. It has been a useful tool in studying soft tissues such as the brain,
cardiovascular system, and cancer. The aim of this systematic review is to critically summarize the health economic
evidence of oncologic PET in the literature.
Methods: Eight electronic databases were searched from 2005 until February 2010 to identify economic evaluation
studies not included in previous Health Technology Assessment (HTA) reports. Only full health economic
evaluations in English, French, or German were considered for inclusion. Economic evaluations were appraised
using published quality criteria for assessing the quality of decision-analytic models. Given the variety of methods
used in the health economic evaluations, the economic evidence has been summarized in qualitative form.
Results: From this new search, 14 publications were identified that met the inclusion criteria. All publications were
decision-analytic models and evaluated PET using Fluorodeoxyglucose F18 (FDG-PET). Eight publications were cost-
effectiveness analyses; six were cost-utility analyses. The studies were from Australia, Belgium, Canada, France, Italy,
Taiwan, Japan, the Netherlands, the United Kingdom, and the United States. In the base case analyses of these studies,
cost-effectiveness results ranged from dominated to dominant. The methodology of the economic evaluations was of
varying quality. Cost-effectiveness was primarily influenced by the cost of PET, the specificity of PET, and the risk of
malignancy.
Conclusions: Owing to improved care and less exposure to ineffective treatments, personalized medicine using
PET may be cost-effective. However, the strongest evidence for the cost-effectiveness of PET is still in the staging
of non-small cell lung cancer. Management decisions relating to the assessment of treatment response or
radiotherapy treatment planning require further research to show the impact of PET on patient management and
its cost-effectiveness. Because of the potential for increased patient throughput and the possible greater accuracy,
the cost-effectiveness of PET/CT may be superior to that of PET. Only four studies of the cost-effectiveness of PET/
CT were found in this review, and this is clearly an area for future research.
Background
Positron emission tomography (PET) is a three-dimen-
sional diagnostic imaging technology in nuclear medi-
cine measuring physiological function by looking at
various functions of the body. It is a non-invasive diag-
nostic imaging tool using chemical neurotransmitters
such as dopamine in Parkinson’s disease or radiophar-
maceuticals such as the radiolabelled glucose analogue
Fluorodeoxyglucose F18 (FDG) in oncology.
PET was introduced in the 1970 s [1]. Intensive
research activities in various PET applications gradually
evolved to its clinical use first in neuropsychiatric disor-
ders and cardiology, then in oncology. Oncology is now
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the most important application of PET. In oncology,
PET can be used for [2]:
• Tumour detection and differential diagnosis of
benign and malignant tumours
• Tumour staging and prognostic stratification
• Evaluation of treatment response
• Restaging and detection of recurrent cancer
• Radiation treatment planning
• Development of new anticancer drugs
Furthermore, PET can have different places in the
diagnostic pathway [3]: at the beginning of the pathway
as a triage, at the end of the pathway as an add-on, or
as a replacement for an existing diagnostic procedure in
the pathway.
The most recent innovation in PET scanners is the
dual-modality PET/CT. By combining radiological (CT)
and nuclear medicine (PET) imaging modalities, it is
possible to add anatomical to functional information.
This study presents a systematic review of the cost-
effectiveness of PET for the diagnosis and management
of cancer. The aim of this systematic review is not to
assess the clinical effectiveness of PET in oncology, but
to appraise the cost-effectiveness of PET imaging in can-
cer management compared with non-invasive and inva-
sive diagnostic modalities. After reading this systematic
review, the reader should be able to: (1) describe onco-
logic PET and PET/CT indications for which economic
evidence has already been shown; (2) illustrate the diffi-
culties of evaluating the cost-effectiveness of innovative
health technologies such as PET and PET/CT within the
scope of the full diagnostic and treatment pathway; and
(3) recognize the necessity for future prospective trial-
based economic evaluation studies of oncologic PET
and PET/CT. For more information on the clinical
effectiveness of PET, the interested reader is referred to
the Health Technology Assessment (HTA) report con-
ducted by Facey et al. [4], which gives a detailed over-
view of the clinical effectiveness of FDG-PET in various
cancers. Recommendations for the use of FDG-PET in
oncology have also been published by Fletcher et al. [5].
Recently, an article regarding evidence (diagnostic effec-
tiveness and cost-effectiveness) and methodological
approaches for conducting economic evaluations of
oncologic PET and PET/CT has been published by Buck
et al. [2]. However, this article is not a systematic review
and does not report on the specific characteristics of
decision-analytic models assessing the cost-effectiveness
of PET and PET/CT in oncology.
Methods
Only full health economic evaluations (cost-effective-
ness, cost-utility, cost-benefit analyses) comparing a
PET-based strategy with different invasive and non-inva-
sive diagnostic strategies in the clinical work-up of can-
cer patients were considered for inclusion. Furthermore,
only fully published economic evaluations in English,
French, or German were included. Economic evaluations
included in two previous HTA reports of PET [6,7] were
excluded to avoid duplication of efforts in reviewing and
synthesizing evidence. A list of excluded studies on eco-
nomic evaluation assessment with reasons for exclusion
is provided in Table 1.
The following databases were searched from January
2005 to February 2010 for relevant economic evalua-
tions concerning the use of PET imaging in oncology:
Cochrane Library, DARE, EMBASE, HTA Database,
NHS EED, PubMed, RePEc, and Web of Science. The
search strategies used text words and corresponding
indexing terms to capture all relevant studies. In Addi-
tional file 1, the full search strategies are provided.
As this literature review of PET was not restricted to
FDG-PET, the search strategy developed by Mijnhout et
al. [8] for a comprehensive search of the FDG-PET lit-
erature was not used. In addition to the electronic data-
base searches, the internet was searched by Google and
Google Scholar. Furthermore, citation tracking was per-
formed using Google Scholar, and a manual search of
the reference lists of recent reviews and included publi-
cations was undertaken.
Several reliable, comprehensive, and user-friendly
checklists are available to assess the quality of health
economic evaluations. The most widely used is the
checklist of Drummond and Jefferson developed by the
BMJ Economic Evaluation Working Party for the British
Medical Journal [9]. However, the BMJ checklist does
not provide detailed coverage of several key issues rele-
vant to decision-analytic models such as model type,
structural assumptions, cycle length, and health states
[10]. Thus, to guide the quality assessment of the mod-
els used in the economic evaluations of PET, the quality
assessment tool for decision-analytic models established
by Philips et al. [11] was applied by two independent
reviewers. This checklist covers three key dimensions of
study quality: structure, data, and consistency. In this
review, each item in the checklist had four possible
responses: 1 for ‘yes’, 0 for ‘no/not reported’, ? for
‘unclear’, and NA for ‘not applicable’. A summary score
was not applied because a quality scoring system was
not considered to be sufficiently reliable and valid as a
means of quality assessment [12]. The appraisal of eco-
nomic evidence favouring or opposing the use of PET
for patients with cancer was based on the three key ele-
ments of the checklist established by Philips et al. [11]:
structure, data, and consistency. The economic evidence
was appraised as limited if one or more of these key ele-
ments were not fulfilled. By using this checklist, the
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validity of included studies, i.e. the risk of bias in indivi-
dual studies, could also be assessed.
For the data collection process, a data extraction sheet
was developed (based on the Centre for Reviews and
Dissemination’s data extraction template). The data
extraction sheet for each study is available from the
author on request. In Additional files 2 and 3, a sum-
mary of the considered data items can be found. Infor-
mation was extracted from each included study on: (1)
cancer/management decision; (2) author, year, country;
(3) comparison; (4) patient group (base case); (5) mea-
sure of effectiveness; (6) incremental analysis; (7)
method, perspective; (8) effectiveness (per patient); (9)
cost (per patient); (10) incremental cost-effectiveness;
and (11) sensitivity analysis.
Results
Overview of economic evaluations of oncologic PET
From the systematic database search, 431 publications
were identified. The full text of articles was investigated
if the health technology appeared to be PET from the
title and abstract and if quantitative economic results
were reported. In all, 66 full copies were retrieved and
assessed for eligibility. Finally, 14 publications met the
inclusion criteria for this review, all of which were
model-based economic evaluations and published in the
English language: diagnosis of a solitary pulmonary
nodule [13], staging of recurrent ovarian cancer [14],
staging of liver metastases from colorectal cancer [15],
staging of pulmonary metastases from malignant mela-
noma [16], staging of recurrent nasopharyngeal carci-
noma [17], staging of head and neck cancer [18], staging
of breast cancer [19], follow-up of non-small cell lung
cancer (NSCLC) [20], and staging of NSCLC [21-26].
No further study was retrieved by citation tracking.
A flowchart for the selection of economic evaluation
studies can be found in Figure 1.
Eight publications were cost-effectiveness analyses; six
were cost-utility analyses. The studies were from Australia,
Table 1 List of excluded studies on economic evaluation
assessment with reason for exclusion
Reference Reason for exclusion
1. Barnett et al. 2010 [44] Cost study
2. Basu, Rubello 2008 [45] Review
3. Biersack 2009 [46] Review
4. Bunyaviroch, Coleman 2006 [47] Review
5. Buscombe, O’Rourke 2007 [48] Review
6. Chua et al. 2008 [49] Review
7. Chuck et al. 2005 [50] Cost study
8. Cleemput et al. 2005 [6] Health technology assessment
report
9. Cleemput et al. 2008 [51] Methodology paper
10. De Geus-Oei et al. 2006 [52] Review
11. Devaraj et al. 2007 [53] Review
12. Eloubeidi et al. 2005 [54] Cost study
13. Facey et al. 2007 [4] Health technology assessment
report
14. Goh 2006 [55] Comment
15. Gould 2006 [41] Review
16. Graham 2009 [56] Comment
17. Hayashi et al. 2005 [28] Research question
18. Herbertson et al. 2009 [57] Review
19. Heinrich et al. 2005 [58] Cost study
20. Herder et al. 2006 [59] Cost study
21. Hoekstra et al. 2006 [60] Methodology paper
22. Juweid, Cheson 2006 [61] Review
23. Krug et al. 2009 [62] Cost study
24. Krug et al. 2008 [63] Cost study
25. Krug et al. 2007 [64] Methodology paper
26. Kwee et al. 2008 [65] Review
27. Mattar 2007 [66] Review
28. Meyers et al. 2006 [67] Research question
29. Moulin-Romsee et al. 2008 [68] Cost study
30. Nosotti et al. 2008 [69] Cost study
31. Pertile 2009 [70] Methodology paper
32. Pertile et al. 2009 [71] Cost study
33. Plathow et al. 2008 [72] Cost study
34. Poulou et al. 2009 [73] Cost study
35. Remonnay et al. 2009 [74] Cost study
36. Remonnay et al. 2008 [75] Cost study
37. Rowan 2008 [76] News
38. Sloka, Hollett 2005 [77] Review
39. Spiro et al. 2008 [78] Review
40. Strobel et al. 2007 [79] Cost study
41. Sun et al. 2008 [80] Review
42. Takahashi et al. 2007 [81] Review
43. Uyl-de Groot et al. 2010 [82] Cost study
44. Van den Bruel et al. 2007 [83] Methodology paper
Table 1 List of excluded studies on economic evaluation
assessment with reason for exclusion (Continued)
45. Van Tinteren et al. 2006 [84] Comment
46. Van Hooren et al. 2009 [85] Cost study
47. Von Schulthess et al. 2006 [27] Review
48. Watson et al. 2006 [86] Review
49. Yap et al. 2005 [87] Cost study
50. Yasunaga 2009 [88] Outcome evaluation study
51. Yasunaga et al. 2006 [89] Outcome evaluation study
52. Zubeldia et al. 2005 [90] Cost study
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Belgium, Canada, France, Italy, Taiwan, Japan, the Nether-
lands, the United Kingdom, and the United States. In the
base case analyses of these studies, cost-effectiveness
results ranged from dominated to dominant. In Additional
files 2 and 3, the characteristics of the economic evaluation
studies and their main results are presented.
All publications provide an economic evaluation on a
model basis. All modelling studies evaluated FDG-PET,
i.e. PET using FDG as the radiotracer. Several publica-
tions built upon, revised, or extended previous decision
models. Some articles provided new decision models.
One study converted an existing decision tree to a Mar-
kov model [25]. Von Schulthess et al. [27] suggest that
the cost-effectiveness of integrated PET/CT is superior
to that of PET alone in some indications, because of
both the higher diagnostic accuracy of integrated PET/
CT and the potential for higher patient throughput.
Only four studies [14,16,18,20] evaluated the cost-
effectiveness of this new diagnostic imaging modality.
Staging of breast cancer
Only one study could be identified that assessed the
cost-effectiveness of PET for the preoperative axillary
staging of breast cancer. In their model-based economic
evaluation, Sloka et al. [19] compared PET and axillary
lymph node dissection (ALND) in selected patients with
ALND in all patients. A cost-effectiveness analysis of
these two diagnostic strategies was undertaken using
decision tree modelling to estimate the costs and effects
for each strategy. The time horizon of the study was
from the initial diagnostic studies to the final treatment
of all treatment modalities (e.g. radiation therapy or
modified radical mastectomy). The perspective adopted
in the economic analysis was that of the hospital. The
base case was defined as a 55-year-old woman with
stage I or II breast cancer. Included in this cost-effec-
tiveness analysis were the costs of diagnostics (PET,
ALND) and the costs of treatment (chemotherapy,
radiotherapy, breast-conserving surgery, and modified
radical mastectomy). The PET strategy was strictly dom-
inating, as it incurred lower costs and resulted in an
increase in life expectancy. This result was relatively
robust to sensitivity analysis. The authors found that
PET for staging breast cancer may benefit patients in
terms of an increase in life expectancy, and the hospital
in terms of reduced costs. Owing to methodological
deficiencies, the study quality is considered to be lim-
ited. In particular, the meta-analysis performed by the
authors was not of high methodological quality. Further-
more, overhead costs, palliative care costs, and costs
associated with quality of life were not considered. In
addition, the authors did not compare their findings
with those from other studies, and the use of probabilis-
tic sensitivity analysis would have captured the issue of
uncertainty in the model parameters better.
Staging of liver metastases from colorectal cancer
Only one study was found that evaluated the cost-effec-
tiveness of PET in the management of patients with
metachronous liver metastases after curative resection of
colorectal cancer. Lejeune et al. [15] used a decision tree
model to compare two diagnostic strategies: CT versus
CT followed by PET. The base case was defined as a
68-year-old patient with suspected metachronous liver
metastases detected by ultrasonography during follow-
up. The economic analysis was carried out from the per-
spective of the health care system and the time horizon
of the model was the patient’s lifetime. The costs of
diagnostic tests (CT, magnetic resonance imaging
(MRI), PET, and liver biopsy) and treatment procedures
(exploratory surgery, surgery, and palliative treatment)
were included. As CT followed by PET was both more
effective and less costly than CT alone, it was found to
be the dominant strategy. Lejeune et al. concluded that
CT+PET was as effective as CT alone in terms of life
expectancy, but less expensive mainly because of cost
savings resulting from a decrease in inappropriate sur-
geries. The sensitivity analysis showed the robustness of
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Figure 1 Flowchart for selection of economic evaluation
studies.
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Staging of pulmonary metastases from malignant
melanoma
Only one study could be retrieved that assessed the cost-
effectiveness of PET/CT in staging pulmonary metastases
from malignant melanoma. Krug et al. [16] used a Mar-
kov model over a 10-year period to compare two differ-
ent surveillance programmes in patients with suspected
pulmonary metastases from malignant melanoma: PET/
CT or whole-body CT. The study was carried out from
the perspective of the health care system. The following
costs were included in the analysis: screening (visit, blood
sampling and chest X-ray), surgery and complications,
chemotherapy and complications, palliative treatment,
PET/CT, and CT. The PET/CT strategy was strictly
dominating, as it incurred lower costs and resulted in an
increase in life-months gained. The authors concluded
that integrating PET/CT in the management of patients
with high-risk malignant melanoma appeared to be less
costly and more accurate by avoiding 20% of futile sur-
geries as well as by providing a small survival benefit at
10 years. In this study, the issue of data identification was
not appropriately addressed, and the rationale for the
model structure was unclear. However, the issue of
uncertainty was satisfactorily addressed using a probabil-
istic sensitivity analysis, the findings of which were exten-
sively illustrated and described.
Staging of recurrent nasopharyngeal carcinoma
Since 2005, the cost-effectiveness of PET in the staging
of recurrent nasopharyngeal carcinoma has only been
assessed by Yen et al. [17]. They used a decision tree
model to evaluate the cost-utility of PET in detecting
local recurrences of nasopharyngeal cancer after treat-
ment. The base case consisted of a 46-year-old male
with suspected recurrent nasopharyngeal cancer at fol-
low-up. In their study, three different diagnostic strate-
gies were compared: MRI only, PET only, and PET after
an uncertain result from MRI (MRI-PET strategy). The
economic analysis only included the costs of diagnostic
tests (MRI and PET). The incremental cost per quality-
adjusted life-year (QALY) gained over MRI was US
$1,389 for PET and US$462 for MRI-PET. The results
were sensitive to the probability of uncertain MRI and
the cost ratio of PET to MRI. Yen et al. concluded that
MRI followed by PET was the most cost-effective strat-
egy, but PET alone could become the preferred strategy
on account of the cost of PET decreasing at a faster rate
than the cost of MRI. However, the authors’ conclusions
should be considered with caution, because there were
several limitations to their economic analysis. First, the
two imaging techniques were not described well, and it
is not clear why the MRI alone strategy was considered
for inclusion, because it was found to be ineffective in
detecting recurrent nasopharyngeal carcinoma. The
perspective and time horizon of the model were not
reported. Only the costs of MRI and PET were included
in the economic analysis, so other direct health
resources, which were not included, might have influ-
enced the overall study findings. The price year was not
reported, and the discounting of costs and health bene-
fits would have been appropriate as the time horizon
seemed to be the patient’s lifetime. Furthermore, the uti-
lity values were based on the Visual Analogue Scale
being commonly considered to be inferior to the stan-
dard gamble or time trade-off methods. Finally, the
issue of uncertainty was not appropriately addressed as
only univariate and multivariate sensitivity analyses were
carried out on a few parameters, and the validity of the
data sources was not reported.
Staging of head and neck cancer
Only one study reported the cost-effectiveness of PET/
CT for staging head and neck cancer. Sher et al. [18]
assessed the cost-effectiveness of PET/CT as a predictor
of the need for adjuvant neck dissection (ND) compared
with ND for all patients. A Markov model was devel-
oped to describe health states in the 5 years after che-
moradiotherapy in a 50-year-old man with node-positive
stage IVA (i.e. T1-3 N2 M0) squamous cell carcinoma
of the oropharynx. The following three strategies were
compared: dissect all patients, dissect patients with resi-
dual disease (RD) on CT, and dissect patients with RD
on PET/CT. The costs of diagnostics (CT and PET/CT)
and treatment (immediate ND, salvage ND, salvage sur-
gery for local recurrence, chemotherapy for metastasis,
hospice care) were included. ND for patients with RD
on PET/CT was found to be the dominant strategy. The
model has some limitations, and thus should be consid-
ered with caution. The perspective of the model was not
stated, and the primary decision-maker was not speci-
fied. Furthermore, the data sources used to develop the
structure of the model were not specified. Concerning
the key theme of data, the issue of data identification
and the assessment of uncertainty were not appropri-
ately addressed, because data identification methods
were not reported in detail, and methodological and
structural uncertainty and systematic differences
between patient subgroups were not considered.
Staging of non-small cell lung cancer
Several studies evaluated the cost-effectiveness of PET
for staging NSCLC. To determine the cost-effectiveness
of PET for mediastinal staging of potentially operable
NSCLC from the health care system perspective, Alza-
houri et al. [21] developed a decision tree model. Four
diagnostic strategies were compared: CT only, PET for
negative CT, PET for all patients with anatomical CT, i.
e. PET for the staging decision and CT for anatomic
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location of mediastinal nodes whereas size was ignored,
and CT plus PET for all patients. The base case was
defined as a 65-year-old patient, in whom NSCLC had
been histologically established and assessed as operable.
The time horizon was not explicitly stated, but seemed
to be the patient’s lifetime. The following costs were
included: CT, PET, cervical mediastinoscopy, surgery,
and chemoradiation. In comparison with CT only,
which was used as the baseline strategy, PET for all with
anatomical CT was found to be dominant, whereas the
CT and PET for all strategy was found to be dominated
by the baseline strategy. The incremental cost-effective-
ness ratio (ICER) of PET for negative CT versus CT
alone was €33,165 per life-year gained. Sensitivity ana-
lyses showed the robustness of the results. Alzahouri et
al. concluded that PET for all with anatomical CT was
the most cost-effective strategy. In this study, the pri-
mary decision-maker was not specified, and the ratio-
nale for the model structure was less clear. Further, the
time horizon of the model was not explicitly stated, and
the issue of data identification was not appropriately
addressed. However, Alzahouri et al. compared their
results extensively with those from other studies.
Bird et al. [24] used a decision model to evaluate the
cost-effectiveness of PET in the management of poten-
tially operable patients with NSCLC. Two diagnostic
strategies were compared: conventional work-up
(CWU), consisting of an X-ray, a chest CT scan, and
bronchoscopy, followed by whole-body PET versus
CWU alone. These two diagnostic strategies were
applied to two subgroups of NSCLC patients: patients
with a negative CT scan (CT-negative patients) and
patients with a positive CT scan (CT-positive patients).
The cost of diagnostic tests (PET, mediastinoscopy) and
the cost of treatment (surgery, radiotherapy, and che-
motherapy) were included. The incremental cost per
QALY gained for the CT-negative strategy was A
$14,581 and A$52,039 for the CT-positive strategy. Bird
et al. concluded that there was much uncertainty sur-
rounding the base case analysis, particularly in CT-posi-
tive patients. In this study, the issue of data
identification was appropriately addressed. Bird et al.
provided a detailed summary table of the studies found
in their literature review. There were three cost-utility
analyses [26,28,29], three cost-effectiveness analyses
[22,30,31], and two comparisons of costs and effects
[32,33], in addition to two randomized controlled trials
[34,35]. Most studies suggested that PET is likely to be
cost-effective, particularly in CT-negative patients.
Further, in this study, the issue of uncertainty was
extensively illustrated and described. However, a graphi-
cal representation of the model structure was not pro-
vided. Finally, the authors stated that the perspective
was societal but, given the perspective assumed, not all
relevant costs were included.
Kee et al. [25] converted an existing decision tree
model of the impact of PET on preoperative staging of
NSCLC to a Markov model to include patient-elicited
utilities. Based on the Markov model, the expected value
of perfect information (EVPI) associated with three
sources of uncertainty (the accuracy of PET, the accu-
racy of CT, and the patient-related utility of a futile
thoracotomy) was estimated. The following costs were
included: PET, mediastinoscopy, surgery, radical radio-
therapy, chemotherapy, and best supportive care. The
ICER of the strategy with PET versus the strategy with-
out PET was £6,704 for a 50-year-old, £8,385 for a 60-
year-old, £10,636 for a 70-year-old, and £13,785 for an
80-year-old. The model confirmed the cost-effectiveness
of PET and showed that the EVPI associated with the
utility of futile thoracotomy exceeded that associated
with measures of diagnostic accuracy. This study has
several limitations. The perspective of the analysis was
not reported. The rationale for the model structure, the
statement of scope/perspective, and the structural
assumptions were not clear. Another limitation concerns
the issue of data identification. Further, the four princi-
pal types of uncertainty were not all addressed.
To evaluate the cost-effectiveness of the introduction
of PET in the clinical management of lung cancer
patients, Mansueto et al. [23] compared three different
diagnostic strategies: CT alone, PET for indefinite CT,
and PET for all. For each of these strategies, expected
costs and benefits, as measured by life-years gained,
were estimated using decision tree models. The perspec-
tive of the health care system was adopted in the study.
The cost of diagnostic tests and surgical procedures
were included. When compared with CT alone, the
additional costs per life-year gained were €2,508 when
using PET for indefinite CT and €415 when using PET
for all. In the sensitivity analyses, PET for all remained
the most cost-effective strategy. The authors stated that
their results generally agreed with those from other eco-
nomic evaluations [22,30,31]. However, neither the
rationale for the model structure nor the structural
assumptions were sufficiently clear. The time horizon of
the model was not reported. Further, the issue of data
identification and the issue of uncertainty were not
appropriately addressed.
The modelling study commissioned by NICE [26] was
built upon the Health Technology Board for Scotland
(HTBS) and Dietlein models [29,31]. The authors con-
sidered two groups of patients who were expected to
benefit most from PET. The first group were patients
with normal-sized lymph nodes on CT (i.e. negative CT
results) being considered for PET (surgery model). The
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second group consisted mainly of those patients with
enlarged nodes on CT (i.e. positive CT results) who
were being considered for radical radiotherapy (radio-
therapy model). In the surgery model, three strategies
were considered. In the first strategy, patients went
straight to thoracotomy. In the second strategy, the
patients had a mediastinoscopy and then received either
radical radiotherapy (N2/3) or thoracotomy (N0/1). In
the third strategy, patients had a PET scan and then
received either active supportive care (M1), thoracotomy
(N0/1, M0), or mediastinoscopy (N2/3, M0). The
authors found that the mediastinoscopy strategy was
dominated by the PET strategy. Compared with the
thoracotomy strategy, the PET strategy resulted in 22%
fewer futile thoracotomies, 1% fewer surgical deaths,
and a better selection of patients for radical radiother-
apy. This resulted in an increase of 0.04 QALYs per
patient. The ICER of the PET strategy compared with
the thoracotomy strategy was £7,200 per QALY gained.
Sensitivity analyses showed that the base case result was
not sensitive to any single parameter other than unit
costs. In the radiotherapy model, only two strategies
were evaluated. The first strategy was that all patients
go straight to radiotherapy, and the second strategy was
that all patients have a PET scan and then receive active
supportive care (M1), thoracotomy (N0/1), or radical
radiotherapy (N2/3). In comparison with the radiother-
apy strategy, the PET strategy resulted in less futile
radiotherapy and some patients benefiting from curative
surgery. However, some patients had unnecessary sur-
gery, and some missed radical radiotherapies. The esti-
mated additional cost was £9,489 per QALY gained. As
in the surgery model, the decision to opt for PET was
not sensitive to any single parameter other than unit
costs. The authors compared their results extensively
with those from the HTBS model [29] and the PLUS
study [34], and explained any differences between them.
Although the publication was commissioned by NICE,
the primary decision-maker was not specified. Further,
the selection of the comparators was not explicitly justi-
fied, and the issue of uncertainty was not appropriately
addressed.
In the cost-effectiveness analysis by Nguyen et al. [22],
the objective was to evaluate the cost-effectiveness of
PET in the management of potentially operable NSCLC
in Quebec, Canada. A decision tree model was devel-
oped to predict the costs and effects of using PET scan-
ning as a means of detecting mediastinal and distant
metastases. Two diagnostic strategies were compared:
CT alone and initial CT followed by whole-body PET.
The viewpoint adopted in the economic analysis was
that of the health care system. Only the direct costs of
the health care system were included in the economic
analysis. The ICER was C$4,689 per life-year gained. In
the univariate sensitivity analysis, the ICER of CT plus
PET ranged from C$3,000 to C$5,000 per life-year
gained. If the threshold ICER was set at C$50,000 per
life-year gained, the authors found that 95% of the
Monte Carlo simulations would be below this threshold.
The authors reported that their findings were similar to
those from other studies. Nguyen et al. concluded that
PET is an intervention that requires an acceptable
investment for each life-year gained. Overall, the study
was of good methodological quality.
Follow-up of non-small cell lung cancer
Only one study reported on the cost-effectiveness of
PET/CT in the follow-up of NSCLC. The cost-utility
analysis by van Loon et al. [20] was based on a Markov
model, with a hypothetical cohort of NSCLC patients
treated with curative radiotherapy with or without che-
motherapy, and a 5-year time horizon. The study objec-
tive was to assess the long-term cost-effectiveness of
three follow-up strategies with different imaging modal-
ities 3 months after therapy: PET/CT-based follow-up,
chest CT-based follow-up, and conventional follow-up
with a chest X-ray. Additionally, a strategy of perform-
ing a PET/CT scan only in asymptomatic patients was
considered. Asymptomatic patients were defined as
patients with no symptoms 3 months after treatment.
The perspective of the health care system was adopted
in the study. The costs of diagnostic tests (initial proce-
dure and subsequent follow-up), radical treatment (adre-
nal resection and radical radiotherapy), palliative
radiotherapy, palliative chemotherapy, and death (can-
cer-related terminal care or death from other causes)
were included in the economic analysis. The incremen-
tal cost per QALY gained compared with conventional
follow-up was €264,033 for CT and €69,086 for PET/
CT. For PET/CT in the subgroup of asymptomatic
patients, the ICER was €42,265 per QALY gained. In the
whole study group, the probabilistic sensitivity analysis
showed that there was considerable uncertainty regard-
ing the optimal follow-up strategy. At a ceiling ratio of
€80,000 per QALY, the PET/CT-based follow-up in
asymptomatic patients only had the highest probability
of being cost-effective (73%). The authors found that the
PET/CT-based follow-up was potentially cost-effective
and was economically more attractive than the
CT-based follow-up, especially in the subgroup of
asymptomatic patients. Overall, the study used robust
methodology. However, the reporting of some data
sources was limited, and the internal and external valid-
ity of the study was not explicitly investigated.
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Staging of recurrent ovarian cancer
Only one study could be retrieved that assessed the
cost-effectiveness of PET/CT in staging recurrent ovar-
ian cancer. Mansueto et al. [14] evaluated the economic
impact of the introduction of PET/CT in the early
detection of suspected ovarian cancer recurrence based
on a decision tree model. Clinical data used in the eco-
nomic evaluation were taken from Mangili et al. [36].
The measure of benefits used in the economic analysis
was the number of surgical procedures avoided. The
study population consisted of 32 patients. Three differ-
ent diagnostic strategies were compared: CT only, PET/
CT for negative CT, and PET/CT for all patients. In
comparison with CT alone, the PET/CT for all strategy
resulted in an ICER of €227 per surgery avoided. PET/
CT for negative CT was found to be dominated by CT
only, because the first was more expensive, but less
effective. Mansueto et al. concluded that the introduc-
tion of PET/CT was cost-effective and changed the clin-
ical management of patients with suspected ovarian
cancer recurrence towards more appropriate treatment.
Especially because of the small sample size, the study
results should be considered with caution. Further, the
rationale of the model structure was not established
well, and the issues of data identification and assessment
of uncertainty were not appropriately addressed.
Diagnosis of a solitary pulmonary nodule
Since 2005, the cost-effectiveness of PET in diagnosing
solitary pulmonary nodules has only been evaluated by
Lejeune et al. [13]. In their cost-effectiveness analysis, a
decision tree model was used to compare the cost-effec-
tiveness of PET with that of standard imaging modalities
in managing solitary pulmonary nodules. The diagnostic
strategies evaluated were: wait and watch (WW), PET
and anatomical CT (PET strategy), i.e. CT only to define
the location, and CT followed by PET (CT+PET). The
base case was defined as a 65-year-old man currently
smoking 1.5 packs per day, with a 2-cm solitary pul-
monary nodule (SPN) without calcification, specula and
enlargements of mediastinal lymph nodes, and a malig-
nancy risk of 43%. The costs of diagnostic tests (radio-
graphy, CT, PET, and transthoracic needle biopsy) and
the costs of surgical procedures (video-assisted thoracic
surgery, wedge resection, and lobectomy) were included.
From the French health care system perspective, the
incremental cost per life-year gained over WW was
€4,790 when using PET and €3,022 when using CT
+PET. In comparison to the PET strategy, CT+PET was
found to be the dominant strategy. The results of the
sensitivity analysis showed that the CT+PET strategy
remained the most cost-effective strategy when the risk
of malignancy was between 5.7% and 87%, whereas WW
was more cost-effective between 0.3% and 5%. The
authors concluded that CT+PET was cost-effective in
diagnosing a solitary pulmonary nodule in patients with
a malignancy risk of at least 5.7%. This study was found
to be of good methodological quality.
Discussion
Summary of economic evidence for PET and PET/CT in
oncology
The technology of PET can be applied to different indi-
cations in oncology. At present, limited evidence is
available on the cost-effectiveness of PET in the staging
of breast cancer, liver metastases from colorectal cancer,
pulmonary metastases from malignant melanoma, recur-
rent nasopharyngeal carcinoma, head and neck cancer,
or recurrent ovarian cancer, and in the follow-up of
NSCLC. Hence, no sound conclusions can be drawn on
the cost-effectiveness of PET and PET/CT in the diag-
nostics of these indications. Since 2005, the most exten-
sive evidence has been provided by six studies on the
cost-effectiveness of PET in staging NSCLC.
Methodology of the economic evaluations
As shown in Additional files 4 and 5, the evaluations
were of varying methodological quality, with some
deviating from economic evaluation standards. For
instance, in several studies, the perspective of the model
was not stated, and in none of the studies was the pri-
mary decision-maker clearly specified, although one
publication [26] was commissioned by NICE.
In general, the quality of the results largely depends
on the quality of the model and the quality of the under-
lying data. Issues covered under the key theme of data
relate to data identification methods and the assessment
of uncertainty. None of the studies addressed all four
types of uncertainty. Probabilistic sensitivity analysis
was only performed in six models. Most of the health
economic evaluations relied on univariate sensitivity
analysis. The sensitivity analyses revealed that cost-
effectiveness was primarily influenced by the cost of
PET, the specificity of PET, and the risk of malignancy.
The issue of generalizability to other settings was partly
addressed in the sensitivity analyses. As all studies iden-
tified were model-based economic evaluations, data
identification is key for the quality of such economic
evaluation studies. Table 2 provides an overview of the
data sources used to populate the models.
The level of reporting of the methods of deriving and
identifying estimates of measures of effectiveness made
it difficult to ascertain their validity, i.e. whether the
best available evidence was used to populate the model.
This selective reporting may result in a publication bias.
A further problem was that the effectiveness data were
often not derived from recently published studies, which
Langer BMC Health Services Research 2010, 10:283
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Table 2 Overview of data sources used to populate the models
Staging of breast cancer
Sloka et al. 2005 [19] Data sources Accuracy data: From literature (MEDLINE, Current Contents, EMBASE; completed in December
2003; details of literature search given); the authors conducted a meta-analysis using 12 published
PET studies of staging axillary lymph node metastases; Life expectancy: From literature; life
expectancies calculated by authors using the DEALE method; Costs: From literature; Mortality:
Mortality estimated by authors; Quality of life: Not relevant.
Dates to which
data relate
The PET accuracy data were derived from studies published between 1989 and 2001. The price
year was 2000.
Staging of liver metastases from colorectal cancer
Lejeune et al. 2005 [15] Data sources Accuracy data: From literature, second liver biopsy sensitivity from expert opinion, PET accuracy
data were taken from three published studies; Life expectancy: Burgundy Digestive Cancer
Registry, life expectancies calculated by authors using the DEALE method; Costs: The costs of the
diagnostic procedures were obtained from ‘Nomenclature Générale des Actes Professionnels’. The
cost of hospital stay required for liver biopsy and the cost of treatment procedures were based
on the national reimbursement rate for the medical department of the Dijon University Hospital.
The length of hospitalization for symptomatic treatment was estimated on the basis of the
national hospital database on diagnosis-related groups. Other resource quantities were based on
expert opinion; Mortality: From literature; Quality of life: Not relevant.
Dates to which
data relate
The PET accuracy data were derived from three studies published between 1997 and 2002. The
price year was 2004.
Staging of pulmonary metastases from malignant melanoma
Krug et al. 2010 [16] Data sources Accuracy data: From literature, PET accuracy data were taken from three published studies; Life
expectancy: The life expectancies were calculated by running the model over different time
periods and until the entire cohort died; Costs: The unit cost values of hospitalization, drugs,
surgery, diagnostic procedures, and the direct health care-related out-of-pocket expenses of
patients were obtained from the current public prices published by the RIZIV/INAMI (Health
Insurance Institution in Belgium). A micro costing approach was used to calculate the true actual
costs of performing a PET/CT study. Resource quantities were based on the resources used by a
cohort of patients followed in standardized administrative databases of 19 hospitals between
2005 and 2006 identified by the Diagnosis Related Groups (DRG) codes; Mortality: From literature;
Quality of life: Not relevant.
Dates to which
data relate
The PET accuracy data were taken from three studies published between 2006 and 2007. The
price year was 2009.
Staging of recurrent nasopharyngeal carcinoma (NPC)
Yen et al. 2009 [17] Data sources Accuracy data: From literature, probability of an uncertain MRI result estimated by authors, PET
accuracy data were taken from four published studies; Life expectancy: From literature and from
life tables from the Department of Health, Executive Yuan, Taiwan, 2002; Life expectancies
calculated by authors using the DEALE method; Costs: Based on reimbursements from National
Health Insurance, Taiwan; Mortality: From literature; Quality of life: Utilities elicited from 10
recurrent NPC patients and 10 oncologists involved in the management of these patients.
Dates to which
data relate
The PET accuracy data were taken from four studies published between 2002 and 2004. The price
year was not reported.
Staging of head and neck cancer
Sher et al. 2010 [18] Data sources Accuracy data: From literature, the PET accuracy data were taken from a meta-analysis of the role
of PET in the follow-up of head and neck squamous cell carcinoma following radiotherapy or
chemoradiotherapy; Life expectancy: The (quality-adjusted) life expectancy was calculated by
running the model; Costs: Costs were taken from the published literature and publicly available
Medicare payment schedules; Mortality: From literature; Quality of life: QALYs were calculated
using utilities that were taken from literature or based on authors’ assumptions.
Dates to which
data relate
The meta-analysis of PET was published in 2008. The price year was 2006.
Staging of recurrent ovarian cancer
Mansueto et al. 2009 [14] Data sources Accuracy data/Life expectancy/Mortality: From Mangili et al. [36]; Costs: The costs were based
on DRG tariffs; Quality of life: Not relevant.
Dates to which
data relate
The clinical study by Mangili et al. was published in 2007.The price year was 2006.
Staging of non-small cell lung cancer (NSCLC)
Alzahouri et al. 2005 [21] Data sources Accuracy data: From literature, PET accuracy data were taken from the cost-effectiveness analysis
of Dietlein et al. [31] and from a meta-analysis by Gould et al. [91]; Life expectancy: From the
cost-effectiveness analysis by Dietlein et al.; Costs: PET and chemoradiation from literature, CT and
cervical mediastinoscopy from ‘Nomenclature Générale des Actes Professionnels’, surgery from
‘Echelle Nationale des Coûts’; Mortality: From literature; Quality of life: Not relevant.
Langer BMC Health Services Research 2010, 10:283
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Table 2 Overview of data sources used to populate the models (Continued)
Dates to which
data relate
The PET accuracy data were derived from two studies published between 2000 and 2003. The
price year was not reported.
Bird et al. 2007 [24] Data sources Accuracy data: From literature, PET accuracy data were taken from the HTBS [29] and from the
NCCAC model [26]; Life expectancy: Life expectancies were taken from the cost-effectiveness
analysis by Dietlein et al. [31]; Costs: From literature and from the Australian National Hospital
Cost Data Collection; the chemotherapy costs were estimated using the HTBS model, the
Rosenthal study [92], and Australian data; Mortality: Mortality rates were taken from the cost-
effectiveness analysis by Dietlein et al.; Quality of life: QALYs were based upon the values used
in the HTBS model.
Dates to which
data relate
The PET accuracy data were derived from two HTA reports published between 2002 and 2005.
The price year was 2006.
Kee et al. 2010 [25] Data sources Accuracy data/Life expectancy/Costs/Mortality: From the HTBS model [29]; Quality of life:
Utilities elicited from 75 NSCLC patients.
Dates to which
data relate
The PET accuracy data were derived from a HTA report published in 2002. The price year was not
reported.
Mansueto et al. 2007 [23] Data sources Accuracy data: From a meta-analysis by Gould et al. [91]; Life expectancy: From the cost-
effectiveness analysis by Dietlein et al. [31]; Costs: From values of diagnosis-related groups and
tariffs of the regional health care system; Mortality: From literature; Quality of life: Not relevant.
Dates to which
data relate




Data sources Accuracy data: From the HTBS model [29]; Life expectancy: From the cost-effectiveness analysis
by Dietlein et al. [31]; Costs: From the NHS reference costs 2002, from literature, or from
individual NHS trusts; Mortality: From the cost-effectiveness analysis by Dietlein et al.; Quality of
life: From the HTBS model.
Dates to which
data relate
The PET accuracy data were taken from the HTBS model published in 2002. The price year was
2002/3.
Nguyen et al. 2005 [22] Data sources Accuracy data: From Pieterman et al. [93]; Life expectancy: From literature; Costs: The costs of
PET were derived from the costs of PET scanning at the Centre Hospitalier Universitaire de
Sherbrooke, Quebec. The costs of hospital stay were determined by the Ministère de la Santé et
des Services Sociaux’s 1998-1999 diagnosis-related groups database. The figures for physicians’




The PET accuracy data were derived from a study published in 2000. The price year was 1998/99.
Follow-up of non-small cell lung cancer (NSCLC)
Van Loon et al. 2010 [20] Data sources Accuracy data: Data on the ability of follow-up strategies to detect progression were taken from
a previous prospective study [94]; Life expectancy: The (quality-adjusted) life expectancy was
calculated by running the model; Costs: The costs of diagnostic procedures and treatment were
taken from the Dutch Health Insurance Board. Other costs were based on the guideline costing
statement provided by the UK National Institute for Health and Clinical Excellence (NICE) and a
published randomized controlled trial; Mortality: From literature, supplemented by expert
opinion; Quality of life: Utility values were taken from a published cross-sectional study,
supplemented by expert opinion.
Dates to which
data relate
The prospective study was published in 2009. The price year was 2007.
Diagnosis of a solitary pulmonary nodule (SPN)
Lejeune et al. 2005 [13] Data sources Accuracy data: From literature, the PET accuracy data were taken from five published studies;
Life expectancy: From literature; Costs: The costs of radiography and CT were obtained from the
‘Nomenclature Générale des Actes Professionnels’. The cost of PET was derived from two French
studies. The costs of treatment procedures were derived from diagnosis-related groups for 2003 in
the public health care sector. The cost of the patient’s hospital stay was derived from the French
national public cost scale, which was derived from a representative sample of French hospitals;
Mortality: From literature; Quality of life: Not relevant.
Dates to which
data relate
The PET accuracy data were derived from different studies published between 1990 and 1998.
The price year was not reported.
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will consequently not reflect current health technology
use and practice.
The estimation of measures of health benefit was mod-
elled using a decision tree or a Markov model, which was
appropriate for the particular study question. All but one
study [14] considered generic outcome measures that
were directly related to the patients’ health. In oncology,
where survival is one of the primary objectives of inter-
ventions, life expectancy is a common outcome measure.
However, the use of a cost-utility analysis using QALYs
could capture the disutility of futile procedures and
would permit comparisons with other health care inter-
ventions. Nguyen et al. [22] pointed out that, in the short
term, it is implausible that PET would improve survival
in cancer patients per se. Rather, its accuracy would
reside in the ability to improve the patients’ quality of life
by avoiding unnecessary, debilitating interventions and
providing the patients with quicker access to treatment.
Six studies considered the impact of PET on quality of
life [17,18,20,24-26].
Most studies used a different time horizon for costs
and health benefits. Whereas health benefits could be
incurred over the patient’s lifetime, the costs were only
incurred over a shorter time horizon. In none of the
studies were the indirect costs included, although one
economic analysis was carried out from a societal per-
spective [24]. Furthermore, details of discounting were
often not provided, and costs and quantities were often
not reported separately.
Finally, in several models, the ICER was not calculated
correctly. The costs and effects of each strategy were
compared with a baseline strategy as opposed to com-
paring each consecutively less effective strategy with the
next most effective non-dominated strategy.
Transferability of the results
Transferability relates to the extent to which the results
obtained are relevant to different settings [10]. Metho-
dological, healthcare system, and population characteris-
tics may determine whether the results can be
generalized [37]. Various groups of authors have sug-
gested checklists for assessing the transferability of
health economic evaluation results between countries,
e.g. [37-40]. However, as these checklists almost exclu-
sively relate to transferring the results of pharma-
coeconomic evaluations, their use in assessing the
transferability of economic evaluation studies in the field
of medical technology can be questioned [39]. Further-
more, as diagnostic pathways can differ from country to
country [6], the results of economic evaluations may
hardly be transferable. Thus, the findings of economic
evaluation studies are only relevant insofar as they
represent current clinical practice in the specific deci-
sion context.
Comparison with other reviews
This economic evaluation assessment augmented the
systematic search undertaken in two previous HTA
reports [6,7]. Thus, economic evaluations included in
both these reports were excluded to avoid duplication of
efforts in reviewing and synthesizing evidence. Further-
more, in this review, studies were limited to those
assessing the cost-effectiveness of oncologic PET and
PET/CT.
The HTA report conducted by Müller et al. [7] com-
pared the cost-effectiveness of PET with common
alternative diagnostic interventions to assess current
economic evidence in the areas of oncology, cardiol-
ogy, and neuropsychiatric disorders. Based on a broad
systematic literature search, 14 oncological studies and
7 cardiological studies were considered for inclusion.
No relevant publications were found in the area of
neuropsychiatric disorders. The methodological quality
of the oncological studies was judged to be good or
very good. Based on the literature review, PET was
considered to be cost-effective only in staging NSCLC.
The authors pointed out the need for further economic
evaluations based on qualitatively high-ranking clinical
trials.
In their HTA report, Cleemput et al. [6] assessed the
clinical effectiveness and cost-effectiveness of PET in
oncology, cardiology, and neurology. Economic evalua-
tions comparing PET with appropriate alternatives were
searched for all these disease areas for which at least
evidence of level 3 (diagnostic thinking efficacy) was
available. Based on a systematic literature search, 22
health economic evaluations were identified and
appraised using the BMJ checklist [9]. The methodology
of the studies was found to be of varying quality. The
authors pointed out that the economic evaluations were
hardly comparable because of different diagnostic path-
ways, models, perspectives, and time horizons. They
concluded that there was only evidence that the addition
of PET to CT for staging NSCLC was cost-effective,
although the incremental benefit in terms of life-years
gained was small.
Table 3 provides a summary of the studies included in
these two HTA reports, but only those studies are con-
sidered that meet the inclusion criteria of this review.
In addition, a review of the cost-effectiveness of PET
for characterizing pulmonary nodules is available from
Gould [41]. Eight studies were identified that evaluated
the cost-effectiveness of PET for SPN characterization.
The author concluded that, despite using different
methods and modelling assumptions, there was remark-
able agreement across these studies. PET was found to
be the most cost-effective strategy when used in patients
with low to moderate pretest probability of malignancy
and indeterminate nodules on CT.
Langer BMC Health Services Research 2010, 10:283
http://www.biomedcentral.com/1472-6963/10/283
Page 11 of 16




Study population* Comparison alternatives Perspective/type of
study
Results and unit* Economic
evidence




Patients with an increase in
carcinoembryonic antigen
levels of > 5 ng/ml during
follow-up testing after the
resection of their primary
CRC
CT+PET versus CT Public payer (Medicare)/
CEA using a model
approach (decision tree)







CT+PET versus CT Hospital/CEA using a
model approach
(decision tree)
Cost savings: C$1,758a Fairb




HNSCC patients with no
evidence of lymph node
involvement










HD patients who have
achieved a partial or
complete response to
induction therapy
(1) All for surveillance; (2) All
for consolidation; (3) CT; (4)
PET after positive CT; (5) (CT)
+PET
Health care system/CUA
using a model approach
(decision model with two
components: decision
tree and Markov model)
Strategies 4 and 5 were found
to be cost-effective, provided
WTP exceeds £1000/LYG, and









62-year-old man with a SPN









Best ICER (€/LYG): 3,218 (4
versus 1); the exploratory
surgery strategy was found to





64-year-old white man (1.5
packs/day smoker) with a
2.5-cm nodule
(1) WW (baseline strategy); (2)
Thoracotomy; (3) CT; (4) CT
+PET
Public payer (Medicare)/
CEA using a model
approach (decision tree)






62-year-old patient with a
new, non-calcified
pulmonary nodule seen on
chest radiograph
40 clinically plausible
sequences of five diagnostic
technologies: CT, PET, TNB,





Best ICER (US$/QALY): 10,935
for strategy 7 (CT: if results
indeterminate, biopsy; if
results benign, WW)/7,625 for
strategy 7/6,515 for CT (if
results indeterminate, surgery;
if results benign, WW)**
Goodb








(1) All for surgery; (2) All for
non-surgical treatment; (3) MS;
(4) PET after negative MS; (5)
PET; (6) MS after negative PET;
(7) MS after positive PET (no
N0/1 M1 disease)
Health care system/CUA
using a model approach
(decision tree)
Best ICER (£/QALY): 58,951 for
CT-positive patients (7 versus
3); 10,475 for CT-negative








assessed as locally resectable
NSCLC without distant
metastases
(1) Conventional staging; (2)
PET in patients with normal-
sized lymph nodes; (3) PET for
all; (4) PET without
supplementary MS if positive
CT and PET; (5) PET without





Best ICER (€/LYG): 143 (2
versus 1); 15,325 (4 versus 2);










CT+PET versus CT Health care system/CEA
using a model approach
(decision tree)





NSCLC, stage IIIB or less
CT+PET versus CT Hospital/CEA using a
model approach
(decision tree)
ICER (¥/LYG): 218,000 Goodb, c
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Limitations of this review
This review has several limitations. First, as the aim of
this review was to undertake a systematic review of
economic evaluations, a systematic review of effective-
ness studies was not carried out. However, systematic
reviews of effectiveness studies are considered to be
the showpiece of evidence-based medicine, and the
value of undertaking systematic reviews of economic
evaluation studies to inform health care decision-
makers is less clear. In the literature, questions remain
as to whether it is actually useful to conduct reviews
of existing economic evaluation studies [42]. A funda-
mental reason for undertaking a review of any type is
that the evidence synthesis will be more useful than
that available from any single study [10]. However,
Anderson [43] argues that the need for systematic
reviews of economic evaluations is unwarranted,
because decision-analytic models are themselves a
well-developed technique of evidence synthesis. How-
ever, the results of this systematic review show
that not all modelling studies of oncologic PET and
PET/CT were of good methodological quality. Thus,
Anderson’s argument can be questioned.
Second, given that the extent of the literature search
was determined by the resources available to the author,
sources searched for economic evaluations did not
include the Health Economic Evaluations Database
(HEED), a specialized database of economic evaluations.
Different search methods (electronic and manual) were
used, and a variety of resources were searched to con-
duct a comprehensive systematic review of economic
evaluation studies. However, it cannot be excluded that
a search in the HEED would reveal additional economic
evaluations. Furthermore, experts were not contacted to
identify unpublished economic evaluation studies.
Therefore, publication bias cannot be excluded comple-
tely, because the full publication of studies is dependent
on the direction and/or strength of their findings, and
positive results are more likely to be published. In addi-
tion, the review was restricted to English, French, or
German publications, and parallel independent assess-
ments reducing the risk of errors during the study selec-
tion process were not performed.
Third, the BMJ criteria list [9] is the most general
quality assessment tool [10]. However, both the study
question and the inclusion criteria required a more spe-
cific quality assessment checklist. Thus, the appraisal of
health economic evaluations followed the framework for
the quality assessment of decision-analytic models devel-
oped by Philips et al. [11]. Given the limitations in
reporting of economic evaluations, study quality was
sometimes difficult to assess. Furthermore, the use of
quality scoring systems is controversially discussed in
the literature. In the recent Centre for Reviews and Dis-
semination (CRD)’s guidance of undertaking reviews in
health care, their use is considered problematic and is
not recommended [10]. Instead of using quality scores,
a narrative critical assessment based on the Philips fra-
mework [11] was performed to reflect individual aspects
of methodological quality. From the high number of
quality criteria, only the most substantial methodological
strengths and weaknesses were reported.
Conclusions
Implications for practice
Owing to improved care and less exposure to ineffective
treatments, personalized medicine using PET may be
cost-effective. However, the strongest evidence for the
cost-effectiveness of PET is still in the staging of
NSCLC. The studies suggested that PET for staging
NSCLC may benefit patients in terms of a (slight)
increase in life expectancy, and the health care system
in terms of cost savings resulting from the number of
invasive procedures avoided. Furthermore, health care
deciders should consider PET as cost-effective for diag-
nosing solitary pulmonary nodules.




64-year-old male with NSCLC (1) CT (MS after positive CT);
(2) PET after negative CT (MS
after positive CT); (3) CT+PET
(MS after positive PET); (4) CT
+PET (MS after positive CT or
positive PET after negative CT)
Public payer (Medicare)/
CEA using a model
approach (decision tree)









CT+PET versus CT Health care system/CEA
using a model approach
(decision tree)
Cost-savings: C$1,455a Goodb
aICER not calculated on account of the clinical insignificance of the outcome difference in terms of life expectancy; bStudy quality was assessed by Cleemput et
al. [6] using the Drummond, Jefferson checklist [9]; cStudy quality was assessed by Müller et al. [7] using a standardized transparency and quality catalogue [104];
*Base case; **Low/intermediate/high probability of malignancy respectively; CRC: colorectal cancer, CEA: cost-effectiveness analysis, CT: computerized
tomography, CUA: cost-utility analysis, HD: Hodgkin’s disease, HNSCC: head and neck squamous cell carcinoma, ICER: incremental cost-effectiveness ratio, LYG:
life-year gained, MS: mediastinoscopy, ng/ml: nanograms per millilitre, NSCLC: non-small cell lung cancer, PET: positron emission tomography, QALY: quality-
adjusted life-year, SPN: solitary pulmonary nodule, TNB: transthoracic needle biopsy, UK: United Kingdom, USA: United States of America, WTP: willingness to pay,
WW: wait and watch.
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Implications for research
Management decisions relating to the assessment of
treatment response or radiotherapy treatment planning
require further research to show the impact of PET on
patient management and its cost-effectiveness. Owing to
the potential for increased patient throughput and the
possible greater accuracy, the cost-effectiveness of PET/
CT may be superior to that of PET. Only four studies
on the cost-effectiveness of PET/CT were found in this
review, and this is clearly an area for future research.
Finally, prospective trial-based economic evaluations are
needed.
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